Differential role of the interleukin-17 axis and neutrophils in resolution of inhalational anthrax

Infection and Immunity

Volumn 80, Issue 1, 2012, Pages 131-142

  Garraud, Kévin ^a   Cleret, Aurélie ^a,c   Mathieu, Jacques ^a   Fiole, Daniel ^a   Gauthier, Yves ^a   Quesnel Hellmann, Anne ^a   Tournier, Jean Nicolas ^a,b  

^a CENTRE DE RECHERCHES   (France)

^b Hôpital Inter Armées du Val de Grâce   (France)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 A; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17F; UNCLASSIFIED DRUG; IL17R PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL CLEARANCE; CYTOKINE RELEASE; DISEASE PREDISPOSITION; INHALATIONAL ATHRAX; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL; A J MOUSE; ANIMAL; C57BL MOUSE; EXPOSURE; IMMUNOLOGY; MOUSE; MOUSE MUTANT; PATHOGENICITY; SECRETION;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; INHALATION EXPOSURE; INTERLEUKIN-17; MICE; MICE, INBRED A; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; RECEPTORS, INTERLEUKIN-17; SURVIVAL ANALYSIS;

EID: 84857078713     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.05988-11     Document Type: Article

References (57)

1. Albrink WS. 1961. Pathogenesis of inhalation anthrax. Bacteriol. Rev. 25:268 -273.
2. Batty S, Chow EM, Kassam A, Der SD, Mogridge J. 2006. Inhibition of mitogen-activated protein kinase signalling by Bacillus anthracis lethal toxin causes destabilization of interleukin-8 mRNA. Cell. Microbiol. 8:130 -138.
3. Borregaard N. 2010. Neutrophils, from marrow to microbes. Immunity 33:657- 670.
4. Breslow JM, et al. 2011. Innate immune responses to systemic Acinetobacter baumannii infection in mice: neutrophils, but not interleukin-17, mediate host resistance. Infect. Immun. 79:3317-3327.
5. Cleret A, et al. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178:7994-8001.
6. Cote CK, Van Rooijen N, Welkos SL. 2006. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect. Immun. 74:469-480.
7. Cote CK, Welkos SL, Bozue J. Key aspects of the molecular and cellular basis of inhalational anthrax. Microbes Infect., in press.
8. Crawford MA, et al. 2010. Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathog. 6:e1001199.
9. Crowe CR, et al. 2009. Critical role of IL-17RA in immunopathology of influenza infection. J. Immunol. 183:5301-5310.
10. Cua DJ, Tato CM. 2010. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 10:479-489.
11. Daley JM, Thomay AA, Connolly MD, Reichner JS, Albina JE. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukoc. Biol. 83:64 -70.
12. Drysdale M, et al. 2005. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J. 24:221-227.
13. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. 2003. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J. Immunol. 170:2106 -2112.
14. Glomski IJ, et al. 2008. Inhaled non-capsulated Bacillus anthracis in A/J mice: nasopharynx and alveolar space as dual portals of entry, delayed dissemination, and specific organ targeting. Microbes Infect. 10:1398-1404.
15. Glomski IJ, Piris-Gimenez A, Huerre M, Mock M, Goossens PL. 2007. Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog. 3:e76.
16. Goossens PL. 2009. Animal models of human anthrax: the quest for the Holy Grail. Mol. Aspects Med. 30:467- 480.
17. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH. 2001. Quantitative pathology of inhalational anthrax. I. Quantitative microscopic findings. Mod. Pathol. 14:482- 495.
18. Guarner J, et al. 2003. Pathology and pathogenesis of bioterrorismrelated inhalational anthrax. Am. J. Pathol. 163:701-709.
19. Harvill ET, Lee G, Grippe VK, Merkel TJ. 2005. Complement depletion renders C57BL/6 mice sensitive to the Bacillus anthracis Sterne strain. Infect. Immun. 73:4420-4422.
20. Hashimoto M, et al. 2010. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207:1135-1143.
21. Heninger S, et al. 2006. Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax. Infect. Immun. 74:6067-6074.
22. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. 2008. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8:142-152.
23. Hoshino A, et al. 2008. MPO-ANCA induces IL-17 production by activated neutrophils in vitro via classical complement pathway-dependent manner. J. Autoimmun. 31:79-89.
24. Hue S, et al. 2006. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 203:2473-2483.
25. Inglesby TV, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236 -2252.
26. Khader SA, Gaffen SL, Kolls JK. 2009. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2:403- 411.
27. Kolls JK, Linden A. 2004. Interleukin-17 family members and inflammation. Immunity 21:467- 476.
28. Koltsova EK, Ley K. 2010. The mysterious ways of the chemokine CXCL5. Immunity 33:7-9.
29. Landsman L, Varol C, Jung S. 2007. Distinct differentiation potential of blood monocyte subsets in the lung. J. Immunol. 178:2000 -2007.
30. Li L, et al. 2010. IL-17 produced by neutrophils regulates IFN-gammamediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J. Clin. Invest. 120:331-342.
31. Liu S, et al. 2010. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 8:455- 462.
32. Mayer-Scholl A, et al. 2005. Human neutrophils kill Bacillus anthracis. PLoS Pathog. 1:e23.
33. McAleer JP, Kolls JK. 2011. Mechanisms controlling Th17 cytokine expression and host defense. J. Leukoc. Biol. 90:263-270.
34. Metchnikoff E. 1890. Etudes sur l'immunité. 3° mémoire: le charbon des rats blancs. Ann. Inst. Pasteur IV:193-212.
35. Moayeri M, et al. 2010. Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog. 6:e1001222.
36. Moayeri M, Leppla SH. 2009. Cellular and systemic effects of anthrax lethal toxin and edema toxin. Mol. Aspects Med. 30:439-455.
37. Nathan C. 2006. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6:173-182.
38. Norman KE, et al. 2003. Combined anticoagulant and antiselectin treatments prevent lethal intravascular coagulation. Blood 101:921-928.
39. O'Brien J, Friedlander A, Dreier T, Ezzell J, Leppla S. 1985. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47:306-310.
40. Raymond B, et al. 2009. Anthrax lethal toxin impairs IL-8 expression in epithelial cells through inhibition of histone H3 modification. PLoS Pathog. 5:e1000359.
41. Ross JM. 1955. On the histopathology of experimental anthrax in the guinea-pig. Br. J. Exp. Pathol. 36:336 -339.
42. Ross JM. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route. J. Pathol. Bacteriol. 73:485- 494.
43. Russell BH, et al. 2008. In vivo demonstration and quantification of intracellular Bacillus anthracis in lung epithelial cells. Infect. Immun. 76:3975-3983.
44. Shapiro S, et al. 2002. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect. Immun. 70:2598 -2604.
45. Stearns-Kurosawa DJ, Lupu F, Taylor FB Jr, Kinasewitz G, Kurosawa S. 2006. Sepsis and pathophysiology of anthrax in a nonhuman primate model. Am. J. Pathol. 169:433- 444.
46. Tournier JN, Mohamadzadeh M. 2010. Key roles of dendritic cells in lung infection and improving anthrax vaccines. Trends Mol. Med. 16:303-312.
47. Tournier JN, Quesnel-Hellmann A, Cleret A, Vidal DR. 2007. Contribution of toxins to the pathogenesis of inhalational anthrax. Cell. Microbiol. 9:555-565.
48. Tournier JN, Rossi Paccani S, Quesnel-Hellmann A, Baldari CT. 2009. Anthrax toxins: a weapon to systematically dismantle the host immune defenses. Mol. Aspects Med. 30:456-466.
49. Tournier JN, Ulrich RG, Quesnel-Hellmann A, Mohamadzadeh M, Stiles BG. 2009. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev. Anti Infect. Ther. 7:219 -236.
50. Twenhafel NA. 2010. Pathology of inhalational anthrax animal models. Vet. Pathol. 47:819-830.
51. Weaver CT, Hatton RD, Mangan PR, Harrington LE. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821- 852.
52. Welkos SL, Friedlander AM. 1988. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 4:53- 69.
53. Welkos SL, Vietri NJ, Gibbs PH. 1993. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb. Pathog. 14:381-388.
54. Werner JL, et al. 2011. Neutrophils produce interleukin-17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection. Infect. Immun. 79:3966 -3977.
55. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. 2011. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS One 6:e17204.
56. Wright GG, Mandell GL. 1986. Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. Med. 164:1700-1709.
57. Ye P, et al. 2001. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194:519 -527.